Close menu




December 16th, 2020 | 10:08 CET

Freenet, Upco International, Ceconomy - clever moves are rewarded

  • Investments
Photo credits: pixabay.com

There are many examples of smart strategic moves that give companies new growth potential. The various facets and their leverage on the share price development are considerable. Let us surprise you!

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: CA9152971052 , DE0007257503 , DE000A0Z2ZZ5

Table of contents:


    FREENET AG - significantly deleveraged

    Freenet is much more than telecommunications. Its mobile communications business characterizes the Group. In addition, the North Germans have built up the second pillar of TV and media since 2016, home entertainment (music and video offers) and smart home applications are some of the keywords. The combination of the two business areas shapes Freenet as a "digital lifestyle provider". A multi-brand strategy (discount to premium) enables it to meet the needs of virtually all customer groups. Around 13 million customers reflect the success.

    Based on the latest figures, it can be said that the Group is holding its own with slight year-on-year revenue and profit growth after nine months. Only the weaker development in TV customers was disappointing. The outlook for the current financial year was confirmed.

    Wisely and with foresight, Freenet refrained from paying a dividend in the summer and generated around EUR 1.1 billion through the sale of a stake. As a result, debt reduction has been significantly improved. In recent months, Freenet also bought back its shares. If the business picks up again, shareholders will benefit in several ways - with rising profits as the number of shares falls and a dividend.

    UPCO INTERNATIONAL INC - UpcoPay as a share price driver?

    Upco International has achieved a lot in 2020 and laid the foundation for further growth. Founded in 2014 and headquartered in Vancouver and New York City, the Company operates in two business segments: telecommunications and digital services. In doing so, Upco operates in niche markets worldwide.
    Its core business is international wholesale voice over IP (VOIP) products. Here, the Company announced in November the acquisition of the Equinox Group, a telecommunications company from the Dominican Republic with wholesale operations in the US and the Caribbean.

    In our opinion, great fantasy lies dormant in solutions for payment services, which can be assigned to the digital services area. At the beginning of the fourth quarter, the Company announced it was launching the beta phase for UpcoPay. UpcoPay is an innovative, secure and convenient direct payment solution between individuals and between individuals and merchants. The goal is to implement an e-wallet after the start-up phase, starting in 2021, to recharge funds or enable payments via an app, among other things. This service will first be available in Europe.

    If Upco succeeds in turning telecommunications customers into additional users for payment services, the Company's growth will accelerate significantly. However, many providers with different solutions are competing in the market. But given the low market capitalization of around CAD 4 million, success should quickly translate into rising sales and share prices.

    CECONOMY AG - Bang for the buck

    The operator of the electronics stores MediaMarkt and Saturn reported a critical step, which the share price honoured with a big jump yesterday. For many years, disputes between the shareholders of the Media-Saturn Holding Company have been a burden. Now Ceconomy announced that it would acquire all of the remaining shares (21.62%) from the existing shareholders. In return, the existing shareholders will receive up to 29.99% of Ceconomy, making them the largest shareholder.

    In the future, Ceconomy will focus on new store concepts and the expansion of eCommerce. The Group's vision is to "build the largest omnichannel platform in Europe." The complete takeover of Media-Saturn-Holding marked an important milestone on this path.

    Ceconomy's stock market value currently stands at EUR 1.8 billion and, in terms of valuation, still leaves room for rising prices. Investors also participate in the Company's success through the high dividend payout ratio of 45 to 55 percent of earnings per share.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read